PharMerica serves bidder a poison pill

Share this article:

Just days after rejecting a $456 million purchase offer, the board at PharMerica Corp. adopted a poison-pill defense. The measure is intended to prevent Omnicare Inc. from obtaining control of PharMerica “in a manner or on terms that are not in the best interests of the company," according to the firm. The maneuver trades rights with PharMerica common stock. These rights would be exercisable should a person or group amass 15% or more of the company's common stock without board approval or announces a tender offer that attempts to do so. The companies are the two largest providers of pharmaceutical services in the long-term care sector.

Share this article:

More in Products

LeadingAge's CAST releases medication management tools

LeadingAge's Center for Aging Services Technologies release new tools last week to help long-term care providers identify the best medication management product.

Butler Mobility updates paint colors for platform lifts

Butler Mobility updates paint colors for platform lifts

Butler Mobility has widened the spectrum of paint color choices for its Incline Platform Lifts line.

NeuroMetrix releases pain management system

NeuroMetrix releases pain management system

NeuroMetrix Inc. has created the SENSUS™ Pain Management System, a wearable neurostimulation technology developed for chronic neuropathic pain, including painful diabetic neuropathy.